|
3-(1H-tetrazol-5-ylamino)cyclohex-2-en-1-one
|
DB07865 |
|
|
(5S)-2-(Cyclooctylamino)-5-methyl-5-propyl-1,3-thiazol-4(5H)-one
|
DB07866 |
|
|
6-CHLORO-4-(CYCLOHEXYLOXY)-3-PROPYLQUINOLIN-2(1H)-ONE
|
DB07867 |
|
|
6-CHLORO-4-(CYCLOHEXYLSULFANYL)-3-PROPYLQUINOLIN-2(1H)-ONE
|
DB07868 |
|
|
6-Chloro-4-[(R)-cyclohexylsulfinyl]-3-propyl-2(1H)-quinolinone
|
DB07869 |
|
|
Rozrolimupab
|
DB05209 |
[Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN).] |
|
SD118
|
DB05207 |
[SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy for neuropathic pain.] |
|
Robalzotan
|
DB06538 |
|
|
Tesaglitazar
|
DB06536 |
[Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.] |
|
CX157
|
DB05205 |
[CX157,3-fluoro-7-(2,2,2,-trifluoroethoxy)phenoxathiin-10,10-dioxide, is a reversible, selective inhibitor of MAO-A designed to have improved oral bioavailability and reduced clearance compared to previous MAO-A inhibitors of this class.] |
|
XL418
|
DB05204 |
[XL418 is a novel anticancer compound.] |
|
Etilevodopa
|
DB06535 |
|
|
(2R)-2-(4-CHLOROPHENYL)-2-PHENYLETHANAMINE
|
DB07860 |
|
|
SPP1148
|
DB05203 |
[SPP1148, the most promising compound from a new series of renin inhibitors for the treatment of hypertension and related end-organ disease.] |
|
Thrombopoietin
|
DB06534 |
|
|
(2R)-N-hydroxy-3-naphthalen-2-yl-2-[(naphthalen-2-ylsulfonyl)amino]propanamide
|
DB07861 |
|
|
Egaptivon pegol
|
DB05202 |
[ARC1779 is a therapeutic aptamer antagonist of the A1 domain of von Willebrand Factor (vWF), the ligand for receptor glycoprotein 1b on platelets. ARC1779 is being developed as a novel antithrombotic agent for use in patients with acute coronary syndromes. ARC1779 is a therapeutic oligonucleotide ("aptamer") which blocks the binding of the A1 domain of vWF to the platelet GPIb receptor, and thereby modulates platelet adhesion, activation, and aggregation under the high shear conditions of coronary arterial stenosis and plaque rupture.] |
|
Ragaglitazar
|
DB06533 |
|
|
V24343
|
DB05201 |
[The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.] |
|
Pafuramidine
|
DB06532 |
[Pafuramidine, a prodrug of furamidine, currently has orphan status for _Pneumocystis jiroveci_ pneumonia.] |
